Pharmaceutical

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical…

9 months ago

Gerresheimer Makes Solid Start to the Financial Year 2024

Organic growth: Revenues +2.8%, adjusted EBITDA +5.9%Capacity expansion in the Americas, Europe and Asia progresses according to planGuidance confirmedDUSSELDORF, GERMANY…

9 months ago

Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a…

9 months ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical…

9 months ago

PharmaCord Announces Appointment of Cindy Padgett to Chief Commercial Officer

JEFFERSONVILLE, IN / ACCESSWIRE / April 10, 2024 / PharmaCord LLC, a leading provider of patient support services for the…

9 months ago

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammationTORONTO, April 10,…

9 months ago

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will…

9 months ago

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…

9 months ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing…

9 months ago